Champix varenicline regulatory update

EMA's CHMP concluded the slightly increased risk of cardiovascular events reported from a meta-analysis of Champix varenicline from Pfizer does not outweigh the benefits of the smoking cessation drug.

Read the full 297 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE